Post by UZH Faculty of Medicine

🔬 Can a single dose of psilocybin unlock new hope for patients with treatment-resistant depression in the real world? In a newly published study, researchers evaluated the real-world effectiveness of psilocybin therapy for treatment-resistant depression. By analysing data from patients treated at the Psychiatrische Universitätsklinik Zürich, the team observed a clinically meaningful reduction in depressive symptoms following the intervention. Crucially, this study is among the very first to demonstrate that psilocybin therapy remains feasible and safe outside the strict confines of controlled clinical trials. 💡 Why it matters: Up to half of individuals with major depressive disorder do not find relief from standard antidepressants, highlighting an urgent need for new therapeutic options. By proving that psilocybin can be safely integrated into routine psychiatric care under specific regulatory frameworks, this research paves the way for broader access to life-changing mental health treatments for those who need them most. The study's first author Johannes Jungwirth remarks: "One of the novelties was that we could plan the therapy individually and shape it towards personal treatment processes, including psilocybin dose and number of dosings.“ 👥 A massive congratulations to Johannes Jungwirth, Samuel Westenhöferöfer, Helena Aicher, Barbora Provaznikova, Golo Kronenberg, Erich Seifritz, Susanne Prinz, Sebastian Olbrich, and the entire team at Psychiatrische Universitätsklinik Zürich and at University of Zurich for this pioneering work! 📖 Be sure to explore the insightful clinical trajectory charts in the full paper to see how patients responded over time. Read the open-access publication here: https://lnkd.in/ePwKQk6x #Neuroscience #MentalHealth #PsilocybinTherapy #DepressionTreatment #Psychiatry